Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinicaltex Research LLC

Neither a doctor nor a teaching hospital

Research payments

$299,707

108 payments

Through program year 2025, Clinicaltex Research LLC is reported as receiving $299,707 in research payments, across 108 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $26,512 3
2024 Research $167 1
2023 Research $27,164 6
2022 Research $38,425 32
2021 Research $54,994 43
2020 Research $65,120 12
2019 Research $87,326 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $184,487 15 payments
  2. Esperion Therapeutics, Inc. $60,814 74 payments
  3. Sanofi US Services Inc. $30,053 6 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $18,580 10 payments
  5. Janssen Research & Development, LLC $4,667 1 payment
  6. Abbott Laboratories $1,106 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $65,325 4 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $60,814 74 payments
  3. Dapagliflozin in Acute Decompensated Heart Failure $43,703 3 payments
  4. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $41,034 4 payments
  5. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $33,925 1 payment
  6. Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study $26,553 4 payments
  7. Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction $18,580 10 payments
  8. A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes $4,667 1 payment
  9. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma $2,000 1 payment
  10. A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record